I Nmune Bio's - INMB market analysis on 25th September 2020

Transaction Date	Recipient	Shares	Type	Price	Value
27th January 2020	Linda F Powers	220,000	Open or private sale	$4.60	$1,012,000.00
11th September 2019	Mark William Lowdell	2,918	Open or private purchase	$6.23	$18,178.56
21st August 2019	Scott Juda	2,500	Open or private purchase	$6.00	$15,000.00
20th August 2019	Raymond Joseph Tesi	100	Open or private purchase	$5.96	$596.00
20th August 2019	Raymond Joseph Tesi	100	Open or private purchase	$5.96	$596.00
20th August 2019	Raymond Joseph Tesi	100	Open or private purchase	$5.96	$596.00
20th August 2019	Raymond Joseph Tesi	100	Open or private purchase	$5.96	$596.00
20th August 2019	Raymond Joseph Tesi	100	Open or private purchase	$5.96	$596.00
20th August 2019	Raymond Joseph Tesi	100	Open or private purchase	$5.96	$596.00
20th August 2019	Scott Juda	2,500	Open or private purchase	$6.00	$15,000.00

I Nmune Bio

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Inmune Bio, Inc. develops immunotherapies that reprogram a patient's innate immune system to fight cancer. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.

Ticker: INMB

Sector: Health Technology

Industry: Biotechnology

SEC Central Index Key (CIK): 1711754

Employees: 4

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis